Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19356992 | 0.87 | LPL (0.46) | LPLLIPGROCK1F2F11 | |
| SCHEMBL4032950 | 0.87 | LPL (0.49) | LPLLIPGROCK1F2F11 | |
| SCHEMBL26923911 | 0.86 | LPL (0.47) | LPLLIPGROCK1F2F11 | |
| SCHEMBL30692214 | 0.86 | LPL (0.47) | LPLLIPGROCK1F2F11 | |
| SCHEMBL25981600 | 0.84 | LPL (0.45) | LPLLIPGROCK1F2F11 | |
| SCHEMBL17645816 | 0.84 | LPL (0.46) | LPLLIPGROCK1F2F11 | |
| SCHEMBL1330068 | 0.84 | LPL (0.46) | LPLLIPGROCK1F2F11 | |
| SCHEMBL586649 | 0.83 | LPL (0.45) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL25981597 | 0.82 | LIPG (0.46) | LPLLIPGROCK1F2F11 | |
| SCHEMBL24363863 | 0.82 | LPL (0.44) | LPLLIPGF2F11PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695241-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| WO-2025119195-A1 | COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024213082-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024099337-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS, AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099336-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| EP-3440938-B1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND THEIR USE AS HERBICIDES | CORTEVA AGRISCIENCE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3398945-B1 | PYRIMIDINYL DERIVATIVES AND THEIR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2022-11-02 | — | — | EP | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| EP-2185530-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | N.V. Organon (NL) | 2010-05-19 | — | — | EP | disclosed |
| EP-1706111-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009016241-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS | N.V. ORGANON (NL) | 2009-02-05 | — | — | WO | disclosed |
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
| EP-1778214-A2 | NOVEL BIPHENYL COMPOUNDS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2006020358-A2 | NOVEL BIPHENYL COMPOUNDS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265345-A1 | Novel Biphenyl Compounds And Their Use | KIF5B, KIF5C, KIF5A | LPL 3405/4885LIPG 2305/4885ROCK1 171/4885 |
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | LPL 2554/4885LIPG 995/4885ROCK1 1675/4885 |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, NR3C2, SRD5A1 | LPL 2622/4885LIPG 3741/4885ROCK1 2500/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | LPL 3188/4885LIPG 1584/4885ROCK1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.